Therapie von Skelettmetastasen

作者: I. J. Diel , H. Seegenschmiedt

DOI: 10.1007/3-540-31303-6_62

关键词:

摘要: Knochenmetastasen im Verlauf von Tumorerkrankungen sind sehr haufig. Die Pravalenz ossarer Metastasen Vergleich zu primaren Sarkomen des Knochens liegt etwa 25mal hoher. Prinzipiell ist jeder bosartige Tumor dazu befahigt, in das Skelett metastasieren. Es aber nur wenige, die gehauft tun. An erster Stelle steht Mammakarzinom, gefolgt vom Prostata- und Bronchial-, Schilddrusen- Nierenzellkarzinom. Diese funf Tumorentitaten fur mehr als 80% aller Skelettmetastasen verantwortlich. Etwa 70–80% Patienten, am Mamma- oder Prostatakarzinom versterben, 50–60% der Bronchial- Schilddrusenkarzinom weisen autoptisch auf (Tabelle 1). durchschnittliche Uberlebenszeit nach Beginn einer Skelettmetastasierung betragt — bei groser Variationsbreite Karzinomen Brustdruse Prostata 2,5 Jahre, beim Bronchialkarzinom deutlich weniger.

参考文章(29)
A H Paterson, T J Powles, J A Kanis, E McCloskey, J Hanson, S Ashley, Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. Journal of Clinical Oncology. ,vol. 11, pp. 59- 65 ,(1993) , 10.1200/JCO.1993.11.1.59
P. Major, A. Lortholary, J. Hon, E. Abdi, G. Mills, H. D. Menssen, F. Yunus, R. Bell, J. Body, E. Quebe-Fehling, J. Seaman, Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials Journal of Clinical Oncology. ,vol. 19, pp. 558- 567 ,(2001) , 10.1200/JCO.2001.19.2.558
G N Hortobagyi, R L Theriault, A Lipton, L Porter, D Blayney, C Sinoff, H Wheeler, J F Simeone, J J Seaman, R D Knight, M Heffernan, K Mellars, D J Reitsma, Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. Journal of Clinical Oncology. ,vol. 16, pp. 2038- 2044 ,(1998) , 10.1200/JCO.1998.16.6.2038
Allan Lipton, Richard L. Theriault, Gabriel N. Hortobagyi, Joseph Simeone, Robert D. Knight, Kathleen Mellars, Dirk J. Reitsma, Maika Heffernan, John J. Seaman, Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. ,vol. 88, pp. 1082- 1090 ,(2000) , 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z
I.J Diel, J.-J Body, M.R Lichinitser, E.D Kreuser, W Dornoff, V.A Gorbunova, M Budde, B Bergström, Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. European Journal of Cancer. ,vol. 40, pp. 1704- 1712 ,(2004) , 10.1016/J.EJCA.2004.03.025
Lee S. Rosen, David H. Gordon, William Dugan, Pierre Major, Peter D. Eisenberg, Louise Provencher, Mary Kaminski, Joe Simeone, John Seaman, Bee-Lian Chen, Robert E. Coleman, Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion Cancer. ,vol. 100, pp. 36- 43 ,(2004) , 10.1002/CNCR.11892
Ann F. Chambers, Alan C. Groom, Ian C. MacDonald, Dissemination and growth of cancer cells in metastatic sites Nature Reviews Cancer. ,vol. 2, pp. 563- 572 ,(2002) , 10.1038/NRC865
I J Diel, V Langrish, Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results British Journal of Cancer. ,vol. 82, pp. 1381- 1386 ,(2000) , 10.1054/BJOC.1999.1077
E.-F. Solomayer, I.J. Diel, G.C. Meyberg, Ch. Gollan, G. Bastert, Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis Breast Cancer Research and Treatment. ,vol. 59, pp. 271- 278 ,(2000) , 10.1023/A:1006308619659
I. J. Diel, E.-F. Solomayer, C. Gollan, Behandlung ossärer Metastasen beim Mammakarzinom Der Gynäkologe. ,vol. 32, pp. 675- 682 ,(1999) , 10.1007/S001290050482